Drugmaker Eli Lilly and Co. (LLY) raised its earnings, adjusted earnings, and revenue guidance for the full-year 2025 while reporting financial results for the third quarter on Thursday. The upward revision was primarily driven by strong underlying business performance across the portfolio and favorable foreign exchange rates.
For fiscal 2025, Eli Lilly now projects earnings in a range of $21.80 to $22.50 per share and adjusted earnings between $23.00 and $23.70 per share. The company expects revenues to be between $63.0 billion and $63.5 billion.
Previously, the company had forecasted earnings in the range of $20.85 to $22.10 per share, adjusted earnings between $21.75 and $23.00 per share, and revenues ranging from $60.0 billion to $62.0 billion.
On average, analysts polled anticipate the company to report earnings of $22.50 per share on revenues of $61.63 billion for the year. It is important to note that analysts’ estimates typically exclude special items.
For more earnings news, earnings calendars, and stock earnings reports, visit rttnews.com.
*The views and opinions expressed herein are those of the author and do not necessarily reflect the views of Nasdaq, Inc.*
https://www.nasdaq.com/articles/eli-lilly-again-boosts-fy25-outlook-update